GIGA-2339
Phase 1Small molecule
GIGA-2339 is one of 17 small molecule programs targeting Hepatitis B Virus Infection. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Hepatitis B Virus Infection
#DrugCompanyPhaseTrials
1Aubagio
SanofiApproved
Hepsera
GileadApproved
Emtriva
GileadApproved
Viread
GileadApproved
Tyzeka
NovartisApproved
Tegretol
NovartisApproved
Quinidine Gluconate
WWyeth-Lederle Vaccines
Approved
Virazole
CConrado Roberto Hoffmann Filho
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GIGA-2339. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- GGigaGen, Inc.